Mineralys Therapeutics 3Q 2026: Net loss $57.3M, EPS $(0.64) — 10-Q Summary

What happened

Mineralys Therapeutics reported a third-quarter 2026 net loss of $57.3 million, wider than its $36.9 million loss a year earlier, and loss per share increased to $0.64 from $0.52. It reported no revenue in either quarter while developing lorundrostat and preparing for a possible launch.

Confirmed

Global impact / market context

The wider loss alongside no revenue shows the company is spending before it has sales. If FDA review leads to approval and a launch, expanded regulatory, medical and market-access teams and continued trials could raise costs first; commercial revenue remains dependent on that outcome.

Analyst inference

The FDA accepted lorundrostat’s hypertension application and set December 22, 2026, as its target decision date. That timetable gives investors a defined regulatory milestone, while the mixed trial record—including a missed primary apnea endpoint—leaves uncertainty around the medicine’s potential uses.

Confirmed

What to watch

1. Watch for the FDA’s decision by its stated December 22, 2026 target date; approval would be a key step toward a potential hypertension launch, not a guarantee of sales. Confirmed
2. Track whether the company provides updates on launch preparation and spending as work shifts toward FDA review, the Transform-HTN extension and pre-commercial capabilities. Confirmed
3. Further Explore-OSA endpoint analyses could clarify the significance of blood-pressure reductions despite missing the primary apnea endpoint, affecting expectations for the medicine’s potential reach. Analyst inference

Evidence

• Original source link unavailable